Shire PLC (SHPG) Shares Sold by TD Asset Management Inc.
TD Asset Management Inc. reduced its stake in Shire PLC (NASDAQ:SHPG) by 20.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 62,867 shares of the biopharmaceutical company’s stock after selling 16,260 shares during the period. TD Asset Management Inc.’s holdings in Shire were worth $9,627,000 at the end of the most recent reporting period.
Other hedge funds also recently modified their holdings of the company. YorkBridge Wealth Partners LLC lifted its position in shares of Shire by 81.7% in the 2nd quarter. YorkBridge Wealth Partners LLC now owns 705 shares of the biopharmaceutical company’s stock worth $116,000 after purchasing an additional 317 shares during the period. Pacer Advisors Inc. purchased a new stake in shares of Shire in the 2nd quarter worth approximately $171,000. Stephens Inc. AR lifted its position in shares of Shire by 22.2% in the 2nd quarter. Stephens Inc. AR now owns 1,256 shares of the biopharmaceutical company’s stock worth $208,000 after purchasing an additional 228 shares during the period. Ingalls & Snyder LLC lifted its position in shares of Shire by 10.8% in the 2nd quarter. Ingalls & Snyder LLC now owns 1,284 shares of the biopharmaceutical company’s stock worth $212,000 after purchasing an additional 125 shares during the period. Finally, Aureus Asset Management LLC purchased a new stake in shares of Shire in the 2nd quarter worth approximately $212,000. Institutional investors and hedge funds own 62.41% of the company’s stock.
Shares of Shire PLC (SHPG) opened at $148.25 on Friday. The firm has a market cap of $44,450.00, a price-to-earnings ratio of 10.23, a PEG ratio of 0.82 and a beta of 1.60. The company has a quick ratio of 0.52, a current ratio of 0.98 and a debt-to-equity ratio of 0.55. Shire PLC has a 52 week low of $137.17 and a 52 week high of $192.15.
Shire (NASDAQ:SHPG) last released its quarterly earnings results on Friday, October 27th. The biopharmaceutical company reported $3.81 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.64 by $0.17. The company had revenue of $3.70 billion for the quarter. Shire had a net margin of 10.95% and a return on equity of 14.41%. The firm’s quarterly revenue was up 7.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.17 EPS. research analysts forecast that Shire PLC will post 15 EPS for the current fiscal year.
SHPG has been the subject of several research reports. Zacks Investment Research raised shares of Shire from a “sell” rating to a “hold” rating in a research report on Friday, October 27th. ValuEngine cut shares of Shire from a “buy” rating to a “hold” rating in a research report on Friday, September 1st. Cowen set a $225.00 target price on shares of Shire and gave the company a “buy” rating in a research report on Sunday, October 29th. Cantor Fitzgerald reissued a “buy” rating and set a $222.00 target price on shares of Shire in a research report on Thursday, September 14th. Finally, Stifel Nicolaus restated a “buy” rating and set a $245.00 price target on shares of Shire in a research note on Sunday, October 8th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and ten have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $212.18.
WARNING: This story was published by Watch List News and is owned by of Watch List News. If you are viewing this story on another site, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this story can be viewed at https://www.watchlistnews.com/shire-plc-shpg-shares-sold-by-td-asset-management-inc/1740742.html.
Shire Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.